Skip to main content

Abcellera Biologics Inc(ABCL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.83
Day High4.00
Open:3.92
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
Tipranks
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Telix Pharmaceuticals (OtherTLPPF) and Johnson & Johnson (JNJ)
Tipranks
AbCellera Biologics (ABCL) Receives a Buy from Truist Financial
Business Wire
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
Motley Fool
CRA: Here’s the TFSA Contribution Room for 2026 and Why Now Is the Best Time to Use It
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), AbCellera Biologics (ABCL) and Cytokinetics (CYTK)
Tipranks
Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks
Tipranks
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts
Tipranks
AbCellera Biologics (ABCL) Receives a Buy from Stifel Nicolaus
Tipranks
BMO Capital Remains a Buy on AbCellera Biologics (ABCL)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), AbCellera Biologics (ABCL)
Business Wire
AbCellera Reports Full Year 2025 Business Results
Business Wire
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
The Globe and Mail
Short sales on the TSX: Where are the sellers as software stocks tumble?
Shopify Inc. headquarters signage in Ottawa on Tuesday, May 3, 2022.
Business Wire
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Business Wire
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
Tipranks
AbCellera Secures Global Settlement and Patent License Deal
Business Wire
AbCellera and Bruker Reach Global Settlement of Patent Litigation
Tipranks
AbCellera Appoints Dr. Stephen Quake to Board
Tipranks
AbCellera Biologics’ Earnings Call: Key Insights
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbCellera Biologics (ABCL), ANI Pharmaceuticals (ANIP) and Summit Therapeutics (SMMT)
Business Wire
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
Tipranks
Stifel Nicolaus Keeps Their Buy Rating on AbCellera Biologics (ABCL)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: CytomX Therapeutics (CTMX), AbCellera Biologics (ABCL)
Tipranks
AbCellera Biologics Reports Q3 2025 Financial Results
Business Wire
AbCellera Reports Q3 2025 Business Results
Tipranks
AbCellera’s ABCL635 Study: A Promising Step for Menopause Treatment
Tipranks
AbCellera’s Phase 1 Study of ABCL575: A Potential Game-Changer?
Business Wire
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
Business Wire
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
Tipranks
TD Cowen Sticks to Its Buy Rating for AbCellera Biologics (ABCL)

Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.